Industry reports
Editor highlights

The Outlook for Pharmaceuticals in Western Europe

We are sorry but this premium report expired!

This market research, not available anymore on the publisher's website, was withdrawn from our database.

To get an alternative report, you can either :

  • Have a look at the list of documents hereafter
  • Launch a new search below

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

DOWNLOAD THESE REPORTS NOW!

Grunenthal GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Grunenthal GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • by Global Data
  • February 2014
  • 40 pages

Summary Grunenthal GmbH (Grunenthal) is a research-based, global pharmaceutical company. The company specializes in the areas of pain therapy, contraception and innovative formulations for established active substances. The company develops, produces and markets pain therapy and gynecology products. ...

Industries: Drug and Medication | Countries: Europe

Astellas Pharma Inc. (4503) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Astellas Pharma Inc. (4503) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Industry report
  • by Global Data
  • February 2014
  • 163 pages

Summary Astellas Pharma Inc. (Astellas) is one of the leading global pharmaceutical companies. It undertakes the research, development, manufacture and commercialization of a wide range of pharmaceuticals. The company's product portfolio comprises both marketed and pipeline products to treat a wide range ...

Industries: Drug and Medication | Countries: United States, Japan, World, Europe

Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • by Global Data
  • January 2014
  • 67 pages

Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Industries: Drug and Medication | Countries: Canada, Germany, Spain, Italy, France, World, Europe, United States, United Kingdom, Japan

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • by Global Data
  • January 2014
  • 191 pages

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two ...

Industries: Drug and Medication | Countries: Spain, Italy, France, Germany, United Kingdom, Europe, World

Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • by Global Data
  • January 2014
  • 64 pages

Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Industries: Drug and Medication | Countries: Canada, Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe

Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • by Global Data
  • January 2014
  • 91 pages

Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Industries: Drug and Medication | Countries: Canada, Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe

Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • by Global Data
  • January 2014
  • 66 pages

Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Industries: Drug and Medication | Countries: Canada, Spain, Italy, France, Germany, World, United States, United Kingdom, Europe, Japan

Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • by Global Data
  • January 2014
  • 65 pages

Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion ...

Industries: Drug and Medication | Countries: Canada, Spain, Italy, France, Germany, World, United States, Europe, Japan

Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • by Global Data
  • January 2014
  • 68 pages

Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion ...

Industries: Drug and Medication | Countries: Canada, Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe

Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • by Global Data
  • January 2014
  • 67 pages

Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Industries: Drug and Medication | Countries: Canada, Spain, Italy, France, Germany, World, United States, United Kingdom, Europe, Japan

24/7 Customer Service

You can call our customer service 24 hours a day / 7 days a week

  • +1 917 267 7886

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.